Antigenics fails to regain Nasdaq compliance
This article was originally published in Scrip
Antigenicshas failed to regain compliance with the Nasdaq's marketplace rule that requires a minimum market value of $50 million in listed securities. The company received a delisting warning at the end of November and had until December 22nd to regain compliance with the rule (Scrip Online, November 28th, 2008). Antigenics now intends to request a hearing with the Nasdaq Listing Qualifications Panel to present its plan to maintain its listing. The company's shares will continue to be listed pending the panel's decision following the hearing.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.